Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Founded by physician-scientists 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.
Basking Ridge (Clinical Operations & Biostats)
110 Allen Road
Basking Ridge, NJ 07920
Industrial Operations and Product Supply
81 Columbia Turnpike
Rensselaer, NY 12144
733 articles with Regeneron Pharmaceuticals, Inc.
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019
Regeneron Pharmaceuticals, Inc. announced that it will report its first quarter 2019 financial and operating results on Tuesday, May 7, 2019, before the U.S. financial markets open.
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments for C5 Complement-Mediated Diseases
Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares.
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science & the Public announced that Ana Humphrey, 18, of Alexandria, Virginia, won the top award in the Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent® (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology's 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents - March 12, 2019
Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin [12-March-2019] TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , March 12, 2019 /PRNewswir
3/12/2019The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval.
With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.
Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis
The next couple of weeks look to be busy for the FDA, with a string of target action dates scheduled. This week marks three scheduled approvals, two for extra indications for already-approved biologics, and the third for a combination treatment for glaucoma. Here’s a look.
Regeneron Pharmaceuticals, Inc. will webcast management participation
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent® in asthma.
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the companies will present a diverse set of clinical and real-world data at the 2019 American Academy of Dermatology Annual Meeting from March 1 to 5 in Washington, D.C.
Regeneron and Sanofi Strongly Disagree with Verdict Upholding Three of Five Amgen U.S. Patent Claims Relating to PCSK9 Antibodies
Praluent® (alirocumab) continues to be available in the U.S.
Regeneron Pharmaceuticals, Inc. will webcast its management presentation at the Cowen 39th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 11, 2019.
This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
Sanofi and Regeneron, following Amgen dropping the price of Repatha in October 2018, have dropped Praluent to $5,850 a year. This is about a 60-percent reduction from the original price for both the 75 mg and 150 mg doses. The new prices will kick in early March.